MannaResearch Acquires Montreal Clinical Research Center
MannaResearch, a group of independent clinical research centers, announces the successful acquisition of Kells Medical Research Group, a Montreal-based clinical investigator site.
MannaResearch
, a group of independent clinical research centers, announces the successful acquisition of
Kells Medical Research Group
, a Montreal-based clinical investigator site.
This acquisition represents the fourth Canadian research center MannaResearch has acquired in the past 15 months and its first in Montreal. With more than 15 years of clinical trial experience, Kells Medical Research Group is one of Montreal’s largest primary care research centers and has a database of more than 200,000 patients. The acquisition brings the MannaResearch patient database to 350,000.
Dr. Graham Wood, MannaResearch’s Chief Executive Officer, explains, “Within the industry, the Kells name is synonymous with quality and experience, making the company a perfect fit for MannaResearch. This acquisition represents a strategic addition to our rapidly expanding group of
sites
, helping us attain our goal of simplifying clinical research in Canada for pharmaceutical companies.”
The acquisition supports MannaResearch’s commitment to growth. Over the next few years MannaResearch plans to add additional research sites within Canada to provide its clients access to consistent, high-quality research centers across the nation.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
